Author(s)

Amr Mohamed Zaghloul¹, Ahmed Sedky², Ali Hussein Mohammed³, Samer A. El-Sawy⁴, Ahmed Abd El Rady Ahmed⁵, Emad Eldin Nabil⁶

¹Tropical Medicine and Gastroenterology Department, Sohag University, Sohag, Egypt.
²Department of Clinical Pathology, Sohag University, Sohag, Egypt.
³Department of Internal Medicine, Sohag University, Sohag, Egypt.
⁴Biochemistry Department, Sohag University, Sohag, Egypt.
⁵Interventional Radiology Department, Alazhar University (Assuit Branch), Assuit, Egypt.
⁶Department of Oncology, Sohag University, Sohag, Egypt.

Background: Hepatocellular carcinoma is the third leading cause of tumor related mortality and develops mostly in patients with chronic liver disease and liver cirrhosis. Human hepatocyte growth factor (HGF) is produced in various organs of the body and is characterized as a multifunctional factor with various biologic activities. Aim: Our aim was to investigate the predictive factors of recurrence specially the role of HGF in patients with HCC treated with TACE. Patients and Methods: one hundred HCC patients treated by TACE who achieved complete response were included and divided into two groups according to disease free survival (DFS) status at 1 year: the non-early recurrence (NER) group (1) and the early recurrence (ER) group (2). Univariate binary logistic regression analysis for the possible risk factors of recurrence showed that AFP, multinodularity and HGF level were significant. Conclusion: high AFP, multinodularity and high HGF were inter-related possible risk factors for 1-year recurrence of HCC in patients with initial remission following TACE.

Hepatocellular Carcinoma, Hepatocyte Growth Factor, Prediction of HCC Recurrence

Zaghloul, A. , Sedky, A. , Mohammed, A. , El-Sawy, S. , Ahmed, A. and Nabil, E. (2020) Predictors of Recurrence of Hepatocellular Carcinoma after Transarterial Chemoembolization: Role of Hepatocyte Growth Factor. Open Journal of Gastroenterology, 10, 151-165. doi: 10.4236/ojgas.2020.106016.